Intrinsic value of Hologic - HOLX

Previous Close

$38.33

  Intrinsic Value

$22.04

stock screener

  Rating & Target

sell

-42%

Previous close

$38.33

 
Intrinsic value

$22.04

 
Up/down potential

-42%

 
Rating

sell

We calculate the intrinsic value of HOLX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 10.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  8.00
  7.70
  7.43
  7.19
  6.97
  6.77
  6.59
  6.43
  6.29
  6.16
  6.05
  5.94
  5.85
  5.76
  5.69
  5.62
  5.56
  5.50
  5.45
  5.41
  5.36
  5.33
  5.30
  5.27
  5.24
  5.22
  5.19
  5.17
  5.16
  5.14
Revenue, $m
  3,304
  3,558
  3,822
  4,097
  4,383
  4,679
  4,988
  5,309
  5,643
  5,991
  6,353
  6,730
  7,124
  7,535
  7,963
  8,410
  8,878
  9,366
  9,876
  10,410
  10,969
  11,553
  12,165
  12,805
  13,476
  14,179
  14,916
  15,687
  16,496
  17,345
Variable operating expenses, $m
  2,615
  2,771
  2,933
  3,101
  3,275
  3,457
  3,646
  3,842
  4,046
  4,259
  3,886
  4,117
  4,358
  4,609
  4,871
  5,144
  5,430
  5,729
  6,041
  6,368
  6,709
  7,067
  7,441
  7,833
  8,243
  8,673
  9,124
  9,596
  10,091
  10,609
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,615
  2,771
  2,933
  3,101
  3,275
  3,457
  3,646
  3,842
  4,046
  4,259
  3,886
  4,117
  4,358
  4,609
  4,871
  5,144
  5,430
  5,729
  6,041
  6,368
  6,709
  7,067
  7,441
  7,833
  8,243
  8,673
  9,124
  9,596
  10,091
  10,609
Operating income, $m
  688
  787
  890
  997
  1,107
  1,223
  1,343
  1,467
  1,597
  1,732
  2,467
  2,614
  2,766
  2,926
  3,092
  3,266
  3,447
  3,637
  3,835
  4,042
  4,259
  4,486
  4,724
  4,973
  5,233
  5,506
  5,792
  6,092
  6,406
  6,735
EBITDA, $m
  1,948
  2,098
  2,254
  2,416
  2,585
  2,760
  2,942
  3,131
  3,328
  3,533
  3,746
  3,969
  4,201
  4,443
  4,696
  4,960
  5,235
  5,523
  5,824
  6,139
  6,468
  6,813
  7,174
  7,552
  7,947
  8,362
  8,796
  9,251
  9,728
  10,228
Interest expense (income), $m
  868
  181
  203
  227
  251
  276
  303
  330
  358
  388
  418
  450
  483
  518
  554
  592
  631
  672
  715
  760
  807
  856
  907
  961
  1,017
  1,076
  1,137
  1,202
  1,269
  1,340
  1,414
Earnings before tax, $m
  508
  584
  663
  745
  831
  920
  1,013
  1,109
  1,209
  1,314
  2,017
  2,130
  2,248
  2,372
  2,500
  2,635
  2,775
  2,922
  3,075
  3,236
  3,404
  3,579
  3,763
  3,956
  4,157
  4,369
  4,590
  4,822
  5,066
  5,321
Tax expense, $m
  137
  158
  179
  201
  224
  248
  273
  299
  327
  355
  545
  575
  607
  640
  675
  711
  749
  789
  830
  874
  919
  966
  1,016
  1,068
  1,123
  1,180
  1,239
  1,302
  1,368
  1,437
Net income, $m
  371
  426
  484
  544
  607
  672
  739
  810
  883
  959
  1,472
  1,555
  1,641
  1,731
  1,825
  1,923
  2,026
  2,133
  2,245
  2,362
  2,485
  2,613
  2,747
  2,888
  3,035
  3,189
  3,351
  3,520
  3,698
  3,884

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  8,626
  9,290
  9,980
  10,698
  11,443
  12,218
  13,024
  13,862
  14,734
  15,642
  16,587
  17,573
  18,600
  19,672
  20,791
  21,959
  23,179
  24,454
  25,787
  27,181
  28,639
  30,165
  31,762
  33,435
  35,186
  37,021
  38,944
  40,959
  43,072
  45,286
Adjusted assets (=assets-cash), $m
  8,626
  9,290
  9,980
  10,698
  11,443
  12,218
  13,024
  13,862
  14,734
  15,642
  16,587
  17,573
  18,600
  19,672
  20,791
  21,959
  23,179
  24,454
  25,787
  27,181
  28,639
  30,165
  31,762
  33,435
  35,186
  37,021
  38,944
  40,959
  43,072
  45,286
Revenue / Adjusted assets
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
  0.383
Average production assets, $m
  6,654
  7,166
  7,698
  8,252
  8,827
  9,424
  10,046
  10,692
  11,365
  12,065
  12,795
  13,555
  14,348
  15,175
  16,037
  16,938
  17,879
  18,863
  19,891
  20,966
  22,091
  23,268
  24,500
  25,790
  27,141
  28,557
  30,040
  31,594
  33,224
  34,932
Working capital, $m
  178
  192
  206
  221
  237
  253
  269
  287
  305
  324
  343
  363
  385
  407
  430
  454
  479
  506
  533
  562
  592
  624
  657
  691
  728
  766
  805
  847
  891
  937
Total debt, $m
  3,768
  4,200
  4,650
  5,117
  5,602
  6,106
  6,631
  7,177
  7,744
  8,335
  8,951
  9,593
  10,262
  10,959
  11,688
  12,448
  13,242
  14,072
  14,940
  15,847
  16,796
  17,790
  18,830
  19,918
  21,059
  22,254
  23,505
  24,817
  26,192
  27,634
Total liabilities, $m
  5,615
  6,048
  6,497
  6,964
  7,449
  7,954
  8,478
  9,024
  9,592
  10,183
  10,798
  11,440
  12,109
  12,807
  13,535
  14,295
  15,090
  15,919
  16,787
  17,695
  18,644
  19,637
  20,677
  21,766
  22,906
  24,101
  25,353
  26,665
  28,040
  29,481
Total equity, $m
  3,010
  3,242
  3,483
  3,733
  3,994
  4,264
  4,545
  4,838
  5,142
  5,459
  5,789
  6,133
  6,492
  6,866
  7,256
  7,664
  8,089
  8,534
  9,000
  9,486
  9,995
  10,527
  11,085
  11,669
  12,280
  12,920
  13,592
  14,295
  15,032
  15,805
Total liabilities and equity, $m
  8,625
  9,290
  9,980
  10,697
  11,443
  12,218
  13,023
  13,862
  14,734
  15,642
  16,587
  17,573
  18,601
  19,673
  20,791
  21,959
  23,179
  24,453
  25,787
  27,181
  28,639
  30,164
  31,762
  33,435
  35,186
  37,021
  38,945
  40,960
  43,072
  45,286
Debt-to-equity ratio
  1.250
  1.300
  1.330
  1.370
  1.400
  1.430
  1.460
  1.480
  1.510
  1.530
  1.550
  1.560
  1.580
  1.600
  1.610
  1.620
  1.640
  1.650
  1.660
  1.670
  1.680
  1.690
  1.700
  1.710
  1.710
  1.720
  1.730
  1.740
  1.740
  1.750
Adjusted equity ratio
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349
  0.349

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  371
  426
  484
  544
  607
  672
  739
  810
  883
  959
  1,472
  1,555
  1,641
  1,731
  1,825
  1,923
  2,026
  2,133
  2,245
  2,362
  2,485
  2,613
  2,747
  2,888
  3,035
  3,189
  3,351
  3,520
  3,698
  3,884
Depreciation, amort., depletion, $m
  1,260
  1,311
  1,364
  1,420
  1,477
  1,537
  1,599
  1,664
  1,731
  1,801
  1,279
  1,356
  1,435
  1,517
  1,604
  1,694
  1,788
  1,886
  1,989
  2,097
  2,209
  2,327
  2,450
  2,579
  2,714
  2,856
  3,004
  3,159
  3,322
  3,493
Funds from operations, $m
  1,630
  1,737
  1,848
  1,964
  2,084
  2,209
  2,338
  2,473
  2,614
  2,760
  2,752
  2,911
  3,076
  3,249
  3,429
  3,617
  3,814
  4,019
  4,234
  4,459
  4,694
  4,940
  5,197
  5,467
  5,749
  6,045
  6,355
  6,680
  7,020
  7,377
Change in working capital, $m
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
  20
  20
  21
  22
  23
  24
  25
  26
  28
  29
  30
  32
  33
  35
  36
  38
  40
  42
  44
  46
Cash from operations, $m
  1,617
  1,723
  1,834
  1,949
  2,068
  2,193
  2,322
  2,456
  2,596
  2,741
  2,732
  2,890
  3,055
  3,227
  3,406
  3,593
  3,789
  3,993
  4,206
  4,430
  4,663
  4,908
  5,164
  5,432
  5,713
  6,007
  6,315
  6,638
  6,977
  7,332
Maintenance CAPEX, $m
  -616
  -665
  -717
  -770
  -825
  -883
  -942
  -1,005
  -1,069
  -1,137
  -1,207
  -1,279
  -1,356
  -1,435
  -1,517
  -1,604
  -1,694
  -1,788
  -1,886
  -1,989
  -2,097
  -2,209
  -2,327
  -2,450
  -2,579
  -2,714
  -2,856
  -3,004
  -3,159
  -3,322
New CAPEX, $m
  -492
  -512
  -532
  -553
  -575
  -598
  -621
  -646
  -673
  -700
  -729
  -760
  -793
  -827
  -863
  -901
  -941
  -983
  -1,028
  -1,075
  -1,125
  -1,177
  -1,232
  -1,290
  -1,351
  -1,416
  -1,483
  -1,554
  -1,629
  -1,708
Cash from investing activities, $m
  -1,108
  -1,177
  -1,249
  -1,323
  -1,400
  -1,481
  -1,563
  -1,651
  -1,742
  -1,837
  -1,936
  -2,039
  -2,149
  -2,262
  -2,380
  -2,505
  -2,635
  -2,771
  -2,914
  -3,064
  -3,222
  -3,386
  -3,559
  -3,740
  -3,930
  -4,130
  -4,339
  -4,558
  -4,788
  -5,030
Free cash flow, $m
  509
  546
  585
  626
  668
  712
  758
  805
  854
  904
  796
  850
  907
  965
  1,026
  1,088
  1,154
  1,221
  1,292
  1,366
  1,442
  1,522
  1,605
  1,692
  1,783
  1,877
  1,976
  2,080
  2,188
  2,301
Issuance/(repayment) of debt, $m
  421
  432
  449
  467
  485
  504
  525
  546
  568
  591
  616
  642
  669
  698
  728
  760
  794
  830
  868
  907
  949
  993
  1,040
  1,089
  1,140
  1,195
  1,252
  1,312
  1,375
  1,442
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  421
  432
  449
  467
  485
  504
  525
  546
  568
  591
  616
  642
  669
  698
  728
  760
  794
  830
  868
  907
  949
  993
  1,040
  1,089
  1,140
  1,195
  1,252
  1,312
  1,375
  1,442
Total cash flow (excl. dividends), $m
  930
  978
  1,034
  1,093
  1,153
  1,217
  1,282
  1,350
  1,421
  1,495
  1,412
  1,492
  1,576
  1,663
  1,754
  1,849
  1,948
  2,051
  2,160
  2,273
  2,391
  2,515
  2,645
  2,781
  2,923
  3,072
  3,228
  3,392
  3,563
  3,743
Retained Cash Flow (-), $m
  -225
  -232
  -241
  -250
  -260
  -270
  -281
  -292
  -304
  -317
  -330
  -344
  -359
  -374
  -390
  -408
  -426
  -445
  -465
  -486
  -509
  -533
  -557
  -584
  -611
  -640
  -671
  -703
  -737
  -773
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  67
  73
  78
  84
  90
  96
  103
  110
  117
  124
  132
  140
  148
  157
  166
  175
  185
  195
  206
  217
  229
  241
  254
  268
  282
  296
  312
  328
  345
  363
Cash available for distribution, $m
  704
  746
  793
  842
  893
  946
  1,001
  1,058
  1,117
  1,179
  1,082
  1,148
  1,217
  1,289
  1,363
  1,441
  1,522
  1,606
  1,695
  1,786
  1,882
  1,983
  2,088
  2,197
  2,312
  2,431
  2,557
  2,688
  2,826
  2,970
Discount rate, %
  9.10
  9.56
  10.03
  10.53
  11.06
  11.61
  12.19
  12.80
  13.44
  14.12
  14.82
  15.56
  16.34
  17.16
  18.02
  18.92
  19.86
  20.86
  21.90
  23.00
  24.15
  25.35
  26.62
  27.95
  29.35
  30.82
  32.36
  33.97
  35.67
  37.46
PV of cash for distribution, $m
  646
  622
  596
  564
  529
  489
  447
  404
  359
  315
  236
  202
  170
  140
  114
  90
  70
  53
  39
  28
  20
  14
  9
  6
  4
  2
  1
  1
  0
  0
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

FINANCIAL RATIOS  of  Hologic (HOLX)

Valuation Ratios
P/E Ratio 14
Price to Sales 3.4
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow 1319
Price to Free Cash Flow -105.5
Growth Rates
Sales Growth Rate 8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 9.1%
Cap. Spend. - 3 Yr. Gr. Rate 6.2%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity 78.8%
Total Debt to Equity 120.2%
Interest Coverage 2
Management Effectiveness
Return On Assets 16.9%
Ret/ On Assets - 3 Yr. Avg. 8.8%
Return On Total Capital 13%
Ret/ On T. Cap. - 3 Yr. Avg. 7%
Return On Equity 30.7%
Return On Equity - 3 Yr. Avg. 17.6%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 53%
Gross Margin - 3 Yr. Avg. 53.7%
EBITDA Margin 83.3%
EBITDA Margin - 3 Yr. Avg. 50.6%
Operating Margin 44.7%
Oper. Margin - 3 Yr. Avg. 26.1%
Pre-Tax Margin 40.2%
Pre-Tax Margin - 3 Yr. Avg. 20.5%
Net Profit Margin 24.7%
Net Profit Margin - 3 Yr. Avg. 13.8%
Effective Tax Rate 38.6%
Eff/ Tax Rate - 3 Yr. Avg. 28.1%
Payout Ratio 0%

HOLX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HOLX stock intrinsic value calculation we used $3059 million for the last fiscal year's total revenue generated by Hologic. The default revenue input number comes from 2017 income statement of Hologic. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HOLX stock valuation model: a) initial revenue growth rate of 8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 9.1%, whose default value for HOLX is calculated based on our internal credit rating of Hologic, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Hologic.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HOLX stock the variable cost ratio is equal to 80.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for HOLX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Hologic.

Corporate tax rate of 27% is the nominal tax rate for Hologic. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HOLX stock is equal to 2.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HOLX are equal to 201.4%.

Life of production assets of 10 years is the average useful life of capital assets used in Hologic operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HOLX is equal to 5.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2785 million for Hologic - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 280 million for Hologic is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Hologic at the current share price and the inputted number of shares is $10.7 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 230.00 95.38  str.sell
DHR Danaher 100.71 56.60  sell
BDX Becton Dickins 253.12 144.47  sell
BSX Boston Scienti 34.41 6.87  str.sell
COO Cooper 257.63 173.94  sell
DGX Quest Diagnost 111.44 103.25  hold

COMPANY NEWS

▶ 7 Bargain Stocks in Today's Pricey Market   [Aug-14-18 04:34PM  Kiplinger]
▶ Nielsen and Sysco climb while VF and Dycom slip   [Aug-13-18 04:32PM  Associated Press]
▶ This Medtech Beat Quarterly Views So Why Is It Toppling?   [Aug-01-18 04:21PM  Investor's Business Daily]
▶ Hologic CEO on innovating in women's health   [08:08AM  Fox Business Videos]
▶ Hologic: Fiscal 3Q Earnings Snapshot   [04:27PM  Associated Press]
▶ Hologic, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ Q3 Earnings Outlook For Hologic   [08:09AM  Benzinga]
▶ MARKETS: Here's why tech stocks are getting whacked again   [Jul-30-18 01:25PM  Yahoo Finance Video]
▶ 7 S&P 500 Companies Whose Debt Scares Me   [Jul-06-18 01:30PM  InvestorPlace]
▶ Is It The Right Time To Buy Hologic Inc (NASDAQ:HOLX)?   [Jun-25-18 03:33PM  Simply Wall St.]
▶ Tesla and AIG tumble while Kraft Heinz and Kellogg climb   [May-03-18 04:29PM  Associated Press]
▶ Hologic: Fiscal 2Q Earnings Snapshot   [May-02-18 04:14PM  Associated Press]
▶ /C O R R E C T I O N -- Hologic, Inc./   [Apr-19-18 07:13PM  PR Newswire]
▶ Edited Transcript of HOLX presentation 6-Mar-17 9:35pm GMT   [Apr-10-18 11:00AM  Thomson Reuters StreetEvents]
▶ 3 Top Healthcare Stocks to Buy Right Now   [Mar-30-18 06:18AM  Motley Fool]
▶ Kahn Brothers Sells New York Times, Citigroup, Hologic   [Feb-12-18 12:54PM  GuruFocus.com]
▶ Hologic beats Street 1Q forecasts   [Feb-08-18 04:09PM  Associated Press]
▶ Hologic, Inc. to Host Earnings Call   [12:20PM  ACCESSWIRE]
▶ Should You Sell Hologic (HOLX) Before Earnings?   [Feb-06-18 08:52AM  Zacks]
▶ Hologic's Cynosure Division Launches TempSure Envi   [Jan-22-18 09:05AM  PR Newswire]
▶ Why Mizuho Securities Upgraded Teva Pharmaceutical to a Buy   [Jan-12-18 09:45AM  Market Realist]
▶ Namal Nawana Elected to Hologic Board of Directors   [Jan-11-18 04:01PM  PR Newswire]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.